The FDA decision is a key victory for ELITE Pharma , which spent years developing an abuse-resistant version of the blockbuster pain pill. The competions original OxyContin
expires Tuesday. Normally such expirations open the door to a slew of cheaper versions from generic drug manufacturers, not this time. However, the FDA decision effectively protects Purdue , Elite and a few others from lower-price competition by requiring generic companies to develop their own abuse-deterrent designs.
Sentiment: Strong Buy